Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations

Background  Vascular endothelial growth factor (VEGF) is recognized a pivotal pro‐angiogenic factor responsible for new blood vessels formation in psoriatic lesion.

[1]  B. Elewski,et al.  Optimizing topical therapies for treating psoriasis: a consensus conference. , 2010, Cutis.

[2]  F. Altruda,et al.  Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies? , 2010, Journal of dermatological science.

[3]  A. Noël,et al.  Histological and transcriptional study of angiogenesis and lymphangiogenesis in uninvolved skin, acute pinpoint lesions and established psoriasis plaques: an approach of vascular development chronology in psoriasis. , 2010, Journal of dermatological science.

[4]  Chun-Lei Zhou,et al.  Corticotropin-releasing hormone attenuates vascular endothelial growth factor release from human HaCaT keratinocytes , 2010, Regulatory Peptides.

[5]  S. Pastore,et al.  Wide-spectrum profile of inflammatory mediators in the plasma and scales of patients with psoriatic disease. , 2010, Cytokine.

[6]  Michael Detmar,et al.  Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis , 2009, Proceedings of the National Academy of Sciences.

[7]  Y. Furukawa,et al.  Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes , 2009, The British journal of dermatology.

[8]  Yuquan Wei,et al.  Recombinant Murine Interleukin 4 Protein Therapy for Psoriasis in a Transgenic VEGF Mouse Model , 2009, Dermatology.

[9]  A. Nofal,et al.  Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  H. Hvid,et al.  Regulatory T cells control VEGF-dependent skin inflammation. , 2009, The Journal of investigative dermatology.

[11]  J. Arbiser,et al.  The role of angiogenesis in the pathogenesis of psoriasis , 2009, Autoimmunity.

[12]  A. Menter,et al.  Topical treatment of psoriasis. , 2009, Current problems in dermatology.

[13]  I. Flisiak,et al.  Plasma TGF-β1, TIMP-1, MMP-1 and IL-18 as a combined biomarker of psoriasis activity , 2008, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[14]  X. Man,et al.  Overexpression of vascular endothelial growth factor (VEGF) receptors on keratinocytes in psoriasis: regulated by calcium independent of VEGF , 2007, Journal of cellular and molecular medicine.

[15]  W. Jurecka,et al.  Vascular endothelial growth factor in patients with psoriatic arthritis. , 2007, Clinical and experimental rheumatology.

[16]  Konstantin V Balakin,et al.  VEGF/VEGFR signalling as a target for inhibiting angiogenesis , 2007, Expert opinion on investigational drugs.

[17]  A. Offidani,et al.  Vegf is Likely a Key Factor in the Link between Inflammation and Angiogenesis in Psoriasis: Results of an Immunohistochemical Study , 2006, International journal of immunopathology and pharmacology.

[18]  S. Ylä-Herttuala,et al.  Biology of vascular endothelial growth factors , 2006, FEBS letters.

[19]  L. Nisticò,et al.  Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis , 2006, Experimental dermatology.

[20]  K. Ballmer-Hofer,et al.  The role of VEGF receptors in angiogenesis; complex partnerships , 2006, Cellular and Molecular Life Sciences.

[21]  I. Flisiak,et al.  Effect of psoriasis treatment on plasma concentrations of metalloproteinase‐1 and tissue inhibitor of metalloproteinases‐1 , 2005, Journal of the European Academy of Dermatology and Venereology : JEADV.

[22]  R. Flisiak,et al.  Plasma transforming growth factor β1 as a biomarker of psoriasis activity and treatment efficacy , 2003, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[23]  R. Flisiak,et al.  ASSOCIATION BETWEEN PSORIASIS SEVERITY AND TRANSFORMING GROWTH FACTOR β1 AND β2 IN PLASMA AND SCALES FROM PSORIATIC LESIONS , 2002 .

[24]  D. Creamer,et al.  Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. , 2002, Archives of dermatology.

[25]  R. Flisiak,et al.  Association between psoriasis severity and transforming growth factor beta(1) and beta (2) in plasma and scales from psoriatic lesions. , 2002, Cytokine.

[26]  B. Bussolati,et al.  Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. , 2001, The American journal of pathology.

[27]  N. Ferrara,et al.  Vascular endothelial growth factor and the regulation of angiogenesis. , 2000, Recent progress in hormone research.

[28]  C E Griffiths,et al.  Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis , 1999, The British journal of dermatology.

[29]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[30]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.